左心室功能障碍在系统性硬化症相关肺动脉高压中的作用
该回顾性观察研究纳入165例接受右心导管和超声心动图的系统性硬化症患者,以左室整体纵向应变> -18%定义左室功能障碍。结果显示系统性硬化症相关肺动脉高压患者中左室功能障碍发生率为74.2%,且合并左室功能障碍者全因死亡风险显著增加(校正后HR 12.64)。
要点
- 系统性硬化症相关肺动脉高压患者中左室功能障碍常见(74.2%)。
- 左室整体纵向应变可识别系统性硬化症相关肺动脉高压患者的左室功能障碍。
- 合并左室功能障碍与全因死亡率升高相关,有助于风险分层。
核心结论
- 系统性硬化症相关肺动脉高压患者中左室功能障碍常见,且与全因死亡率增加相关。
- 左室整体纵向应变可能有助于识别潜在左室功能障碍并用于风险评价。
研究设计与样本
- 回顾性观察研究,纳入165例同时接受超声心动图和右心导管检查的系统性硬化症患者。
- 左室功能障碍定义为斑点追踪超声心动图测得的左室整体纵向应变> -18%。
- 系统性硬化症相关肺动脉高压定义为平均肺动脉压> 20 mmHg。
主要发现
- 系统性硬化症相关肺动脉高压患者中左室功能障碍发生率为74.2%,无肺动脉高压者为51.2%。
- 合并肺动脉高压和左室功能障碍患者的中位生存期为67.9个月(95%CI 38.3-102.0)。
- 校正年龄、性别、系统性硬化症病程和FVC后,与无肺动脉高压且左室功能正常的系统性硬化症患者相比,合并肺动脉高压和左室功能障碍患者全因死亡的风险比为12.64(95%CI 1.73-92.60)。
关键数值与推荐
- 左室功能障碍判定阈值:左室整体纵向应变> -18%。
- 肺动脉高压定义:平均肺动脉压> 20 mmHg。
- 全因死亡风险比:12.64(95%CI 1.73-92.60),校正年龄、性别、系统性硬化症病程和FVC。
- 中位生存期:67.9个月(95%CI 38.3-102.0)。
临床怎么用
- 在系统性硬化症患者接受右心导管评估时,可考虑通过左室整体纵向应变筛查左室功能障碍。
- 对合并左室功能障碍的系统性硬化症相关肺动脉高压患者应加强风险评估与随访。
局限性
- 回顾性观察性设计。
- 单中心研究,样本量有限(165例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In systemic sclerosis (SSc), pulmonary hypertension remains a significant cause of morbidity and mortality. Although conventionally classified as group 1 pulmonary arterial hypertension, systemic sclerosis-related pulmonary hypertension (SSc-PH) is a heterogeneous disease. The contribution of left-sided cardiac disease in SSc-PH remains poorly understood. RESEARCH QUESTION: How often does left ventricular (LV) dysfunction occur in SSc among patients undergoing right heart catheterization and how does coexistent LV dysfunction with SSc-PH affect all-cause mortality in this patient population? STUDY DESIGN AND METHODS: We conducted a retrospective, observational study of 165 patients with SSc who underwent both echocardiography and right heart catheterization. LV dysfunction was identified using LV global longitudinal strain (GLS) on speckle-tracking echocardiography based on a defined threshold of > -18%. SSc-PH was defined by a mean pulmonary artery pressure > 20 mmHg. RESULTS: Among patients with SSc who have undergone right heart catheterization, LV dysfunction occurred in 74.2% with SSc-PH and 51.2% without SSc-PH. The median survival of patients with SSc-PH and LV dysfunction was 67.9 (95% CI, 38.3-102.0) months, with a hazard ratio of 12.64 (95% CI, 1.73-92.60) for all-cause mortality when adjusted for age, sex, SSc disease duration, and FVC compared with patients with SSc without pulmonary hypertension with normal LV function. INTERPRETATION: LV dysfunction is common in SSc-PH. Patients with SSc-PH and LV dysfunction by LV GLS have increased all-cause mortality. This suggests that LV GLS may be helpful in identifying underlying LV dysfunction and in risk assessment of patients with SSc-PH.
引用
- Lui JK, Cozzolino M, Winburn M, et al. Role of Left Ventricular Dysfunction in Systemic Sclerosis-Related Pulmonary Hypertension. Chest. 2023. PMID: 38128607. doi:10.1016/j.chest.2023.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。